Table 1 Clinical characteristics of ACLF patients with different outcomes at 90 daysa
Characteristicsb | ACLF-S n = 55 | ACLF-D n = 47 |
|---|---|---|
Age (yrs.) | 44.7 ± 11.0 | 46.6 ± 12.6 |
Male (No.) | 87.3% (48) | 85.1% (40) |
HBV-DNA level (IU/ml) | ||
 2 × 102–2 × 104 | 27.3% (15) | 25.6% (12) |
 2 × 104–2 × 106 | 52.7% (29) | 36.2% (17) |
 > 2 × 106 | 20.0% (11) | 38.3% (18) |
Laboratory data | ||
 Alanine aminotransferase (U/L) | 232.0 [90.0, 550.0] | 368.0 [104.0, 874.0] |
 Aspartate aminotransferase (U/L) | 140.0 [90.50, 194.0] | 146.0 [105.0, 438.0] |
 Albumin (g/dL) | 31.4 ± 4.1 | 30.6 ± 5.0 |
 Total bilirubin (µmol/l) | 329.7 ± 107.9 | 416.2 ± 130.9*** |
 Alkaline phosphatase (U/L) | 131.0 [95.0, 162.0] | 139.0 [120.0, 173.0] |
 γ-Glutamyl transpeptidase (U/L) | 77.50 [59.0, 118.4] | 81.0 [52.0, 125.0] |
 Creatinine (μmol/L) | 66.0 [54.5, 72.0] | 69.0 [59.5, 100.5]* |
 Sodium (mmol/L) | 137.0 [135.0, 139.0] | 137.0 [134.5, 139.0] |
 White blood cell count (109/L) | 7.3 [5.9, 9.3] | 8.3 [6.6, 11.8] |
 Hemoglobin (g/L) | 125.3 ± 18.0 | 124.5 ± 22.5 |
 Hematocrit (%) | 35.6 ± 5.4 | 35.5 ± 6.1 |
 Platelet count | 132.0 [85.0, 163.5] | 104.0 [70.5, 129.5]* |
 INR | 1.9 [1.7, 2.2] | 2.50 [2.3, 3.3]*** |
 Alpha fetoprotein | 179.8 [66.9, 266.8] | 66.3 [29.3, 140.4] |
Organ failure (No.) | ||
 Liver | 96.4% (53) | 97.9% (46) |
 Coagulation | 18.2% (10) | 55.3% (26)*** |
 Kidneys | 1.8% (1) | 12.8% (6) |
 Brain | 1.8% (1) | 6.4% (3) |
 Lungs | 0 | 0 |
 Circulation | 0 | 0 |
ACLF grade | Â | Significance |
 ACLF-1 | 80.0% (44) | 36.2% (17) |
 ACLF-2 | 20.0% (11) | 55.3% (26) |
 ACLF-3 | 0 | 8.5% (4) |
Severity score | ||
 COSSH-ACLF IIs | 6.7 [6.4, 7.3] | 7.6 [7.3, 8.1]*** |
 COSSH-ACLFs | 5.6 [5.3, 6.1] | 6.7 [6.2, 7.0]*** |
 CLIF-C ACLFs | 39.0 ± 5.6 | 44.5 ± 6.2*** |
 MELD | 22.1 ± 4.0 | 28.6 ± 7.1*** |
 MELD-Na | 23.6 [20.1, 26.1] | 29.0 [25.1, 32.7]*** |
 CTP | 9.0 [9.0, 10.0] | 10.0 [9.0, 11.0] |